Skip to main content
GENETIC TECHNOLOGIES LIMITED logo

GENETIC TECHNOLOGIES LIMITED — Investor Relations & Filings

Ticker · GTG ISIN · AU000000GTG7 LEI · 529900YYKY7FRC90M744 ASX Human health and social work activities
Open in API
Filings indexed 1,303 across all filing types
Latest filing 2009-10-08 AGM Information
Country AU Australia
Listing ASX GTG

About GENETIC TECHNOLOGIES LIMITED

https://gtglabs.com/

Genetic Technologies Limited is a molecular diagnostics company focused on the development and commercialization of predictive genetic risk assessment tools. The company specializes in the geneType platform, which integrates clinical risk factors with polygenic risk scores to provide comprehensive risk assessments for various chronic diseases. Its portfolio includes tests for breast cancer, colorectal cancer, prostate cancer, melanoma, type 2 diabetes, and coronary artery disease. By identifying individuals at high risk of developing these conditions, the company enables healthcare providers to implement personalized screening and preventative health strategies. Genetic Technologies Limited serves clinicians and patients globally, aiming to improve health outcomes through early detection and precision medicine.

Recent filings

Filing Released Lang Actions
AGM Proxy Form 2 pages ?Kb
AGM Information Classification · 100% confidence The document is a proxy form for the Annual General Meeting (AGM) of Genetic Technologies Limited. It includes instructions on how to vote, appoint proxies, and details about the meeting date and location. It also lists items of business such as re-election of directors and appointment of auditor, which are typical agenda items for an AGM. There is no financial data or report content, only voting instructions and proxy appointment information. Therefore, this document is related to AGM Information, specifically proxy materials for the AGM.
2009-10-08 English
Director Appointment/Resignation 1 page ?Kb
Board/Management Information Classification · 100% confidence The document is an ASX announcement dated October 5, 2009, regarding the appointment of Dr. Malcolm Brandon as a non-executive director of Genetic Technologies Limited. It focuses solely on a change in the company's board of directors and provides background information on the appointee. There is no financial data, report, or other regulatory filing content. This fits the category of Board/Management Information (MANG), which covers announcements of changes in the company's board or senior management. The document length is short and specific to this appointment, confirming it is not a report or other filing type.
2009-10-04 English
Initial Director`s Interest Notice 2 pages ?Kb
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3X Initial Director’s Interest Notice' and references ASX listing rule 3.19A.1 and section 205G of the Corporations Act. It details the initial director's relevant interests in securities and contracts, with no securities held. This is a notification of personal share transactions or interests by a company director. The document length is short and focused solely on director's interests, matching the definition of Director's Dealing (DIRS).
2009-10-04 English
Preliminary Final Report 72 pages ?Kb
Regulatory Filings
2009-08-27 English
Appendix 4C - quarterly 8 pages ?Kb
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Quarterly Activities Report and Appendix 4C of the ASX Listing Rules for the quarter ended 30 June 2009.' It contains detailed operational updates, financial cash flow statements, and corporate matters for the quarter. The presence of the Appendix 4C, which is a standard quarterly cash flow report required by the ASX, confirms this is a quarterly report. The document includes substantive financial data such as consolidated cash flow statements, payments to directors, and financing activities, which are characteristic of an Interim / Quarterly Report. It is not merely an announcement or a certification, but a full quarterly report with financial and operational details. Therefore, the appropriate classification is Interim / Quarterly Report (IR). Q4 2009
2009-07-29 English
US Patent Update 1 page ?Kb
Regulatory Filings Classification · 95% confidence The document is an ASX announcement dated June 30, 2009, regarding a US patent update for Genetic Technologies Limited. It discusses a non-final Office Action from the USPTO related to a patent re-examination and provides commentary from the CEO about the patent status and related legal matters. The document is short (2524 characters) and serves as an update or announcement rather than a detailed report or financial filing. There are no financial statements, earnings data, or regulatory certifications. It does not fit into categories like Annual Report, Earnings Release, or Legal Proceedings Report since it is primarily an informational announcement about patent status. Given the nature and length, it best fits the Regulatory Filings (RNS) category, which is a fallback for miscellaneous regulatory announcements that do not fit other categories.
2009-06-29 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.